Darlifarnib's FTI Class Baggage Overshadows Mechanistically Differentiated RCC Combination Bid

Kura Oncology to Present Long-Term Darlifarnib Data in RCC at KCRS

Kura Oncology announced that updated Phase 1a results from the ongoing FIT-001 clinical trial (NCT06026410), evaluating darlifarnib in combination with cabozantinib for advanced renal cell carcinoma (RCC), will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit (KCRS). These long-term follow-up data will highlight darlifarnib’s potential as a combination agent with VEGFR-targeted therapies in heavily pretreated, cabozantinib-naïve patients with refractory RCC. Kura is currently enrolling patients in the randomized Phase 1b dose-optimization portion of FIT-001, comparing darlifarnib plus cabozantinib versus cabozantinib alone, to inform the selection of a recommended Phase 3 dose for a registrational study planned for 2028.

• Kura Oncology will present updated long-term follow-up data from the Phase 1a portion of the FIT-001 study at the 2026 Kidney Cancer Research Summit (KCRS) on July 24, 2026. These results focus on darlifarnib combined with cabozantinib in heavily pretreated, cabozantinib-naïve patients with refractory advanced clear cell renal cell carcinoma (ccRCC), providing further evidence of darlifarnib's potential to enhance VEGFR-targeted therapies.
• Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling. This mechanism aims to counter a key resistance mechanism to targeted therapies, thereby enhancing the depth and durability of response. Kura highlights darlifarnib's potential as a precision combination agent across multiple targeted therapy classes, including VEGF-TKI, KRAS, and PI3Ka inhibitors.
• Kura is actively enrolling patients in the U.S. and E.U. for the randomized Phase 1b dose-optimization portion of the FIT-001 trial, comparing darlifarnib plus cabozantinib against cabozantinib alone in cabozantinib-naïve, refractory, advanced ccRCC. This phase is crucial for selecting a recommended Phase 3 dose for a registrational study anticipated in 2028. The company also plans to evaluate darlifarnib in combination with daraxonrasib for RAS-mutated pancreatic ductal adenocarcinoma.

The Need for Deeper, More Durable Responses in RCC

Despite meaningful advances in targeted therapy and immunotherapy, renal cell carcinoma (RCC) remains a disease with substantial unmet clinical need — metastatic RCC carries a 5-year survival rate of less than 10%, and approximately 20–30% of clear cell RCC patients progress to aggressive metastatic disease. The therapeutic landscape is further complicated by inherent resistance mechanisms, significant toxicity burdens, and the growing complexity of treatment selection across a rapidly expanding armamentarium.

• Broad resistance to conventional therapies: RCC is among the most resistant tumours to chemotherapy, radiotherapy, and hormonal therapy. Response rates to cytokine-based regimens such as IL-2 and IFN-alpha remain in the 10–20% range, with few long-term survivors and no demonstrated survival benefit from IFN-alpha as adjuvant therapy in three separate randomized trials.

• Acquired resistance to targeted agents: Drug resistance to first-line VEGF-targeted therapies frequently emerges through angiogenic escape — the activation of VEGF-independent pathways — rendering frontline TKIs progressively ineffective. When progression occurs following both ICI and TKI therapy, subsequent therapeutic options are markedly limited.

• Toxicity constraints across treatment modalities: High-dose IL-2 produces durable responses in a small subset of patients but is accompanied by formidable toxicity, restricting its use to carefully selected populations. Sunitinib-related toxicity affected approximately 50% of patients in clinical experience, with hypertension, thrombocytopenia, stomatitis, diarrhoea, and fatigue among the most common adverse events; Grade 3 serious adverse events affected up to 10% of patients. Surgical morbidity, thalidomide-associated neurotoxicity, and the significant toxicity profile of stem cell transplantation further constrain the available treatment space.

• Complexity of treatment sequencing and selection: While the number of available therapeutic options continues to grow, selecting the optimal strategy for individual patients has become increasingly challenging. Each agent must be evaluated across dimensions of toxicity, cost, and clinical benefit, with unresolved questions remaining around the timing of cytoreductive nephrectomy, optimal combination versus sequential single-agent approaches, and the value of chronic novel agent therapy.

• Absence of validated predictive biomarkers: Despite focused investigative efforts, no reliable predictive biomarkers for response to specific targeted therapies have been successfully validated to date. This gap impedes rational patient selection and limits the ability to prospectively identify which patients are most likely to derive durable benefit from available regimens.

• Limited durability of responses: Even among patients who do respond to current systemic therapies, durable remissions remain uncommon. The combination of IFN-alpha and IL-2 increases overall response rates compared to monotherapy, yet no improvement in overall survival has been demonstrated, underscoring the critical need for therapies that translate objective responses into meaningful long-term outcomes.

Long-Term Follow-Up from FIT-001 Phase 1a in ccRCC

Recent clinical investigations in renal cell carcinoma span a broad range of intervention types — from targeted HIF-2α inhibition and IO-TKI combinations to real-world dosing strategies and radiotracer-based diagnostics. The studies below, published in 2025–2026, capture key efficacy and safety signals across both clear cell and non-clear cell histologies.

Darlifarnib's Broader Potential as a Precision Combination Agent

Beyond its application in renal cell carcinoma, darlifarnib (KO-2806) is being investigated as a combination agent in KRAS-driven solid tumours, with preclinical evidence supporting its role in overcoming resistance to RAS-directed therapies. The mechanistic rationale centres on darlifarnib's ability to block mTORC1 activation via RHEB while sparing mTORC2, thereby targeting a key resistance node while limiting associated toxicities.

• KRAS-mutant non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) are the two additional indications for which darlifarnib is being trialled, with persistent mTORC1 activity identified as a frequent, nongenetic driver of both inherent and adaptive resistance to RAS inhibition in preclinical models of both tumour types.

• The intervention model is combination therapy, specifically the addition of darlifarnib to tumours already progressing on RAS inhibitors — including mutant-selective RAS inhibitors — resulting in rapid and durable tumour regression in preclinical NSCLC and CRC settings.

• Darlifarnib rescued sensitivity to the pan-RAS inhibitor RMC-6236 in progressing tumours, underscoring its utility as a re-sensitising agent when added to an existing RAS inhibitor backbone rather than replacing it.

• Monotherapy switching was insufficient: transitioning from a mutant-selective to a pan-RAS inhibitor as a single agent produced only tumour stasis in NSCLC and had no meaningful effect on CRC tumour progression, reinforcing the necessity of the combination approach.

Darlifarnib's Strategic Play in Refractory RCC

The ongoing evolution of advanced renal cell carcinoma (RCC) treatment has seen significant strides, particularly with the advent of multi-targeted tyrosine kinase inhibitors (TKIs) like cabozantinib and various immune checkpoint inhibitor (ICI) combinations. Yet, for patients whose disease progresses despite these therapies, especially those who are heavily pretreated and refractory, the need for novel, effective options remains critical. Kura Oncology's darlifarnib, in combination with cabozantinib, is emerging as a potential answer, with updated Phase 1a data slated for presentation.

Cabozantinib is a well-established agent, targeting key pathways like VEGFR, MET, and AXL, and has demonstrated efficacy in both monotherapy and combination settings across various lines of RCC treatment. Darlifarnib, a farnesyl transferase inhibitor, offers a distinct mechanistic approach by inhibiting mTORC1 signaling in endothelial cells. Preclinical evidence suggests this mechanism can enhance the antiangiogenic effects of TKIs and even re-sensitize tumors that have developed resistance. This synergistic potential is what makes the combination particularly intriguing for refractory RCC.

Kura's strategy appears to be a calculated move to carve out a niche in this difficult-to-treat population. By leveraging cabozantinib's known profile, the company aims for an efficient development path, with a randomized Phase 1b dose-optimization study underway to inform a registrational Phase 3 trial planned for 2028. This approach seeks to capitalize on a mechanistic differentiation that could overcome common resistance pathways.

However, the path forward is not without its hurdles:

• Clinical Translation: While preclinical data are promising, demonstrating a significant and durable clinical benefit in heavily pretreated, refractory patients is a high bar.

• Toxicity Management: Cabozantinib is known for its adverse event profile. The addition of darlifarnib could introduce additive toxicities, necessitating careful dose management and potentially impacting patient adherence.

• Competitive Landscape: The RCC market is dynamic, with numerous effective ICI+TKI combinations already approved. Darlifarnib+cabozantinib will need to demonstrate a compelling risk-benefit profile to stand out.

Ultimately, if darlifarnib can successfully translate its preclinical promise into meaningful clinical outcomes, it could offer a valuable new therapeutic avenue for patients with advanced, refractory RCC, extending the utility of TKI-based strategies in a population desperately needing new options. The upcoming data will be crucial in validating this potential.